Alnylam Pharmaceuticalsvs.Neurocrine Biosciences
ALNY vs NBIX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Alnylam Pharmaceuticals is about 2.3× larger than Neurocrine Biosciences by market cap; Neurocrine Biosciences trades at the lower P/E (26.4 vs 69.1); year to date, Neurocrine Biosciences leads (+24.9% vs −24.9%).
Side by side
| ALNY | NBIX | |
|---|---|---|
| Market cap | $39.9B | $17.7B |
| Price | $298.76 | $177.11 |
| Today | −4.5% | −1.9% |
| Return YTD | −24.9% | +24.9% |
| Return 1Y | −7.4% | +31.3% |
| P/E | 69.1 | 26.4 |
| P/S | 9.3 | 5.7 |
| P/B | 37.1 | 5.2 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Alnylam PharmaceuticalsALNY
Pioneer of RNAi medicines for rare and cardiovascular diseases.
Full ALNY profile →Neurocrine BiosciencesNBIX
Biopharma focused on neurological and endocrine diseases (Ingrezza).
Full NBIX profile →More comparisons in Biotech & innovation
See where ALNY and NBIX sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →